Trial reportCancer medicine2026
Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study.
Trial report in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04346381 (An Open-label, Multi-center，Phase II Study of Camrelizumab Combined With Famitinib in the Treatment of Advanced Solid Tumor), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Multi-center，Phase II Study of Camrelizumab Combined With Famitinib in the Treatment of Advanced Solid Tumor
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTo evaluate the outcomes of patients with refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with camrelizumab combined with famitinib following platinum-based chemotherapy.
methodsIn this multicenter, phase 2, single-arm trial, patients with R/M HNSCC who had documented progression after platinum-based chemotherapy were administered camrelizumab 200 mg every 3 weeks and famitinib at 20 mg once daily (cohort 1). The primary endpoint was the objective response rate (ORR). The key secondary endpoints included progression-free survival (PFS), duration of response (DOR), time to objective response (TTR), disease control rate (DCR), overall survival (OS), and safety.
findingsBetween August 07, 2020 and June 22, 2022, a total of 20 patients with R/M HNSCC were enrolled. The median age of the patients was 61 years (range, 37-69). The ORR was 35.0% (95% CI, 15.4-59.2) and the DCR was 55.0% (95% CI, 31.5-76.9). The median TTR was 2.23 months (95% CI, 2.0-8.3), the median DOR was 8.0 months (95% CI, 2.2 to not reach), the median PFS was 4.1 months (95% CI, 1.7-10.3), and the median OS was 8.4 months (95% CI, 3.0-17.0), with a median follow-up duration of 7.2 months (range 0.1 months to 19.6 months). Treatment-related adverse events (TRAEs) of grade ≥ 3 included decreased white blood cell count (15.0%), hypertension (15.0%), pneumonia (15.0%), and tumor bleeding (15.0%). The most common TRAEs of any grade were decreased white blood cell count (50.0%), anemia (50.0%), hypertension (50.0%), and decreased platelet count (45.0%).
interpretationIn this single-arm phase II trial, camrelizumab plus famitinib demonstrated encouraging efficacy and a manageable safety profile in patients with refractory R/M HNSCC. These preliminary findings warrant further investigation.
trial registrationClinicalTrials.gov identifier: NCT04346381.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.